U.S. markets closed

Biocept, Inc. (BIOC)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
4.3600-0.0300 (-0.68%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close4.3900
Open4.3700
Bid4.3000 x 900
Ask4.3200 x 900
Day's Range4.2500 - 4.4100
52 Week Range3.4600 - 13.0000
Volume139,584
Avg. Volume582,054
Market Cap58.434M
Beta (5Y Monthly)0.83
PE Ratio (TTM)N/A
EPS (TTM)-1.5040
Earnings DateMay 11, 2021 - May 17, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est20.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Biocept Provides Update on COVID-19 Testing with More than 350,000 Samples Received to Date
    Business Wire

    Biocept Provides Update on COVID-19 Testing with More than 350,000 Samples Received to Date

    Biocept Provides Update on COVID-19 Testing with More than 350,000 Samples Received to Date

  • Business Wire

    Biocept to Host Key Opinion Leader Webinar to Discuss Its CSF Assay for the Diagnosis of Cancer Involving the Central Nervous System

    Biocept, Inc. (Nasdaq: BIOC) will host a webinar featuring leading neuro-oncologists to discuss the use of the Company’s proprietary cerebrospinal fluid (CSF) assay for diagnosing and managing tumors that have metastasized to the central nervous system (CNS), including the brain or spinal column. Biocept’s CSF assay provides enhanced sensitivity compared with CSF cytology, the current standard of care, and has the added advantage of identifying actionable molecular targets for use in treatment decisions while providing quantitative information needed for assessing treatment response and monitoring disease progression.

  • Business Wire

    Biocept Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, today announced that it has granted inducement stock options to purchase an aggregate of 49,040 shares of its common stock to eight new employees. These inducement stock options have a grant date of March 31, 2021, and were granted as inducements material to the new employees entering into employment with Biocept in accordance with Nasdaq Listing Rule 5635(c)(4).